258: Treating patients in HAPO glucose category 5 to improve maternal and neonatal outcomes: a cost effectiveness analysis

Mission, John; Ohno, Mika; Yanit, Keenan; Pilliod, Rachel A.; Cheng, Yin Cheong; Caughey, Aaron B.

doi:10.1016/j.ajog.2011.10.276

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mission et al 24 used a decision analysis model to compare the cost‐effectiveness of treating patients with GDM versus not treating in the USA. They considered patients in HAPO (Hyperglycemia and Adverse Pregnancy Outcome) Category 5 (top 3%–12% of fasting glucose levels), which is consistent with diagnosis of marginal patients according to the IADPSG recommendations.…”

Section: Hyperglycemia In Pregnancymentioning

confidence: 99%

Maternal health and non‐communicable disease prevention: An investment case for the post COVID‐19 world and need for better health economic data

Kapur

Hod

2020

Intl J Gynecology & Obste

View full text Add to dashboard Cite

An integrated approach to population health, disease surveillance, and preventive care will dominate the health agenda in the post COVID-19 world. Because of their huge burden and the vulnerability imposed during a health crisis, prevention and care of non-communicable diseases (NCDs) will need to be prioritized even further. Maternal and child health are inextricably linked with NCDs and their risk factors. The intergenerational impact of poor maternal nutrition and health conditions during pregnancy, particularly NCD-related pregnancy complications, can be considered as a multiplier of the ongoing pandemic of NCDs. The economic cost of poor maternal health and NCDrelated pregnancy complications is likely very high, but is not adequately researched or documented in the context of long-term population health. Interventions to address NCDs in pregnancy have beneficial effects on short-term pregnancy outcomes; but even more importantly, identifying "at-risk" mothers and offspring opens up the opportunity for targeted early preventive action. Preventive actions to address obesity, hypertension, type 2 diabetes, and cardiovascular diseases have a common lifestyle approachidentifying any one of these problems in pregnancy provides an opportunity to address them all. Cost-benefit analyses that only focus on the short-term and on one condition do not capture the full value of downstream, long-term benefits for population health.This requires urgent attention from FIGO. K E Y W O R D S

show abstract

Section: Hyperglycemia In Pregnancymentioning

confidence: 99%